Stock Price
143.28
Daily Change
0.39 0.27%
Monthly
21.12%
Yearly
46.22%
Q1 Forecast
137.58

Gilead Sciences reported $1.24B in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
ALKERMES USD 165.1M 49K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Amgen USD 538M 300K Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 0 Sep/2025
GlaxoSmithKline GBP 4.03B 119.13M Sep/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
J&J USD 2.41B 584K Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
United Therapeutics USD 42.9M 42.1M Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025